$百奥赛图-B(02_老虎社区_美港股上老虎

$百奥赛图-B(02315)$ 这个抗体分子授权/许可的主要活计跟医生差不多，越老越吃香！若论BD数量，百奥在国内可是数得上号的。
最近发现又BD公告或者新管线公布进展的，资本市场马上有所反应，而之前只要新药没获批，都是不会给估值的，现在创新药确实不缺热钱。
昨天 $南模生物(688265)$ 都补涨了，看看百奥赛图能否中报利好的机会突破IPO后股价高点平台！

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":464196622954816,"tweetId":"464196622954816","gmtCreate":1754354717532,"gmtModify":1754354719981,"author":{"id":4120462527107840,"idStr":"4120462527107840","authorId":4120462527107840,"authorIdStr":"4120462527107840","name":"明大教主","avatar":"https://static.tigerbbs.com/7923b570045ef396e894082089df0a6c","vip":2,"userType":2,"introduction":"长期跟踪A、港美股，擅长结合基本面、技术面深度分析","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"3f8f4b8c193b4343a88817ce07587dbd-1","templateUuid":"3f8f4b8c193b4343a88817ce07587dbd","name":"星级创作者","description":"累计发表精华帖>=3（或有料帖>=10），且30天内发表过至少一篇精华帖（或4篇有料帖）并参与过评论","bigImgUrl":"https://static.tigerbbs.com/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://static.tigerbbs.com/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://www.laohu8.com/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.07","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":12882,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><a href=\"https://laohu8.com/S/02315\">$百奥赛图-B(02315)$</a> 这个抗体分子授权/许可的主要活计跟医生差不多，越老越吃香！ 若论BD数量，百奥在国内可是数得上号的。\n<br>\n最近发现又BD公告或者新管线公布进展的，资本市场马上有所反应，而之前只要新药没获批，都是不会给估值的，现在创新药确实不缺热钱。\n<br>\n昨天 <a href=\"https://laohu8.com/S/688265\">$南模生物(688265)$</a> 都补涨了，看看百奥赛图能否中报利好的机会突破IPO后股价高点平台！</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/02315\">$百奥赛图-B(02315)$</a> 这个抗体分子授权/许可的主要活计跟医生差不多，越老越吃香！ 若论BD数量，百奥在国内可是数得上号的。\n<br>\n最近发现又BD公告或者新管线公布进展的，资本市场马上有所反应，而之前只要新药没获批，都是不会给估值的，现在创新药确实不缺热钱。\n<br>\n昨天 <a href=\"https://laohu8.com/S/688265\">$南模生物(688265)$</a> 都补涨了，看看百奥赛图能否中报利好的机会突破IPO后股价高点平台！</body></html>","text":"$百奥赛图-B(02315)$ 这个抗体分子授权/许可的主要活计跟医生差不多，越老越吃香！ 若论BD数量，百奥在国内可是数得上号的。 最近发现又BD公告或者新管线公布进展的，资本市场马上有所反应，而之前只要新药没获批，都是不会给估值的，现在创新药确实不缺热钱。 昨天 $南模生物(688265)$ 都补涨了，看看百奥赛图能否中报利好的机会突破IPO后股价高点平台！","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"favoriteSize":0,"link":"https://laohu8.com/post/464196622954816","repostId":0,"isVote":1,"tweetType":1,"viewCount":271,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02315","688265"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":312,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/464196622954816"}